Cytokine players keep the faith
But he hopes that Sotio will prevail by focusing on patients who have previously failed checkpoint inhibitors and cancers in which these drugs have not worked.
Cytokine players keep the faith Read More »
But he hopes that Sotio will prevail by focusing on patients who have previously failed checkpoint inhibitors and cancers in which these drugs have not worked.
Cytokine players keep the faith Read More »
Biotechnology startup Cerevance Inc. could earn more than $1 billion through a collaboration with drugmaker Merck & Co. to research potential treatments for Alzheimer’s disease.
Biotech Startup Cerevance Strikes Alzheimer’s Research Deal With Merck Read More »
With Andrew Hall at its helm, IMV has evolved an animal contraceptive into a unique drug delivery platform aimed at creating targeted cancer immunotherapies for humans.
Turning harp seal contraceptives into a ‘new genre’ of cancer treatments Read More »
Cerevance is a central nervous system disorders-focused biotech backed by Bill Gates. Its main program so far has been the Parkinson’s disease therapy CVN424, which
For the first time since discontinuing its late-stage Alzheimer’s program, Merck has found promise on the path forward in the memory-robbing disease.
Psychedelic medicine firm MindMed (Nasdaq: MNMD)has dosed the first patient in a Phase 2b dose-optimization trial of MM-120, a pharmaceutically optimized form of lysergic acid diethylamide (LSD).
MindMed launches Phase 2b to study LSD in generalized anxiety disorder Read More »
PORT-2 is an activator of this population. It has direct impact against tumors in terms of upregulating PD-L1 expression, which we know is favorable because it can
A broad range of serious diseases involve chronic inflammation, which causes both pain and progressive damage. Xalud Therapeutics is developing a locally-delivered, non-viral gene therapy that is designed to harness the ability of interleukin-10 to regulate the immune system and restore homeostasis. The company’s lead indication is in osteoarthritis We spoke to Diem Nguyen, CEO
Using Gene Therapies to Treat Chronic, Inflammatory Conditions Read More »
In this episode, the editorial team spoke with the President and CEO of regenerative medicine biotech Sernova Corp Dr. Philip Toleikis to learn more about how the company is developing a ‘functional cure’ for diabetes.
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group is starting its phase 2 trial on patients with selected advanced/refractory solid tumors.
SOTIO Biotech starts solid tumor trial Read More »
Brad Margus is co-founder and Executive Chairman of Cerevance, a drug discovery company advancing a robust pipeline of targeted treatments for patients with neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease.
SOT101 is an interleukin (IL)-15 superagonist that had demonstrated preclinical efficacy in various tumor models. Specifically, the agent prolonged survival and improved tumor regression in in vivo models. The agent also demonstrated a favorable toxicity profile preclinically.
Treatment With SOT101 and Pembrolizumab Commences in Phase 2 AURELIO-04 Study Read More »
The Business of Biotech caught up with Dr. McArthur at PepGen’s Cambridge headquarters to learn more.
Oligonucleotide Opportunities in DMD with PepGen’s James McArthur, Ph.D. Read More »
Andrew Hall is the CEO of IMV Inc, which has developed a platform based on a lipid-in-oil technology that encapsulates the therapeutic. When injected subcutaneously, the drug remains in a specific location to reinvigorate the immune system to overcome the tumor surveillance that allows cancer to grow.
Portage Biotech is helmed by CEO Ian Walters and CSO Robert Kramer, and backed by three biotech entrepreneurs — UK investor Jim Mellon, ex-Biohaven board member Declan Doogan and early Medivation backer Greg Bailey — who have whipped up a whole slate of different ventures aimed at drug development.
OTX-2002 is our lead Omega Epigenomic Controller™ (OEC) candidate designed to downregulate the expression of c-Myc (MYC), a key gene involved in cellular growth commonly overexpressed in cancer cells. OECs are programmable mRNA medicines that encode a two-part protein: a DNA binding domain that specifies the target location on the DNA, which we call EpiZips™,
Matthew explains, “At Immunome, we believe that the antibodies that these B cells are making have an ability to see the different types of tumor antigens, or the specific epitopes on infectious disease. Our platform allows us to see that disease through the lens of the human B cell. We can interrogate what those antibodies
TFF Pharmaceuticals has leased a plant in Austin, Texas to expand development of its thin film freezing technology, which it says could increase the bioavailability of large molecule drugs.
TFF BOOSTS CAPACITY FOR DRUG SOLUBILITY TECH Read More »
Recce Pharmaceuticals is developing a new class of synthetic anti-infectives that it says can overcome the hyper-cellular mutation of bacteria and viruses.
Combatting Superbugs and Emerging Viruses Read More »
Dr. Judy Chou is the President and CEO of AltruBio which is developing novel immunomodulators to treat immunological diseases such as autoimmune and inflammatory diseases. Their first-in-class agnostic antibody has a unique mechanism to regulate T cell homeostasis. Currently, there is a clinical trial for SR-aGVHD, steroid-refractory acute graft-host disease and an investigation is underway
Jeff Cleland is the Chairman, President, and CEO of Ashvattha Therapeutics, initially focusing on demonstrating the ability to deliver drugs that cross tissue barriers like the blood-brain barrier and the blood-retinal barrier to attack inflammation.
Portage Biotech — which is led by two Bristol Myers Squibb vets, CEO Ian Walters and CSO Robert Kramer — is buying out New York’s Tarus Therapeutics in a $21 million all-stock deal that gives it $3 million worth of liabilities on top of four adenosine receptor antagonists, two of which are already in Phase
Pennsylvania-based Immunome, Inc. said its antibody cocktail, dubbed IMM-BCP-01, “retained activity” against the BA.4/5 and BA.2.12.1 subvariants in pseudovirus testing.
Veru, Immunome Tout Positive Data for COVID-19 Therapeutics Read More »
While the psychedelic approach to mental health has recently achieved some clinical and regulatory validation, executives in the space warn the drugs cannot cure all and barriers to market remain.
Psychedelics Pipeline Overview: R&D Blossoms But No Panacea Among Candidates Read More »
Immunome CEO Purnanand Sarma, Ph.D. joins the Business of Biotech for a discussion on precision antibodies and his company’s discovery platform, which identifies novel therapeutic
Antibody Cocktails With Immunome’s Dr. Purnanand Sarma Read More »
When CEO Avanish Vellanki founded and incorporated Rain Therapeutics on his living room couch in the spring of 2017, there was no drug in development, no money, and a team of only four people. Five years later, after halting the development of its first licensed product, the Newark, CA-based precision oncology company awaits topline results
A Network And Pivot Model For Success In Cancer Drug Development Read More »
Thin-film freezing (TFF) is an advanced formulation process that can produce stable protein particles of submicron size and is potentially ideal for overcoming some of the challenges described above
Improved Formulations to Enable Stable Delivery of Biologics Read More »
“Like the ongoing activities that financial institutions have adopted regarding [their] intentional efforts to be inclusive, the life sciences industry may want to adopt similar approaches to increase the awareness of career opportunities within the field.
Beyond Increments: Black Perspectives on Representation in the Life Sciences Read More »
MeiraGTx today announced top-line data from the Phase 1/2 clinical study MGT009 (NCT03252847) of botaretigene sparoparvovec (formerly referred to as AAV-RPGR), an investigational gene therapy in development for the treatment of patients with X-linked retinitis pigmentosa (XLRP) with disease-causing variants in the RPGR gene.
The experimental Arrowhead Pharmaceuticals drug fazirsiran can reduce the accumulation of a mutant protein by 83% among people with alpha1-antitrypsin deficiency (AAT) disease, according to results from an open-label phase 2 trial involving 16 volunteers.
Drug reduces mutant protein that can lead to fibrosis in rare genetic liver disease Read More »